PRESENTATION

Q4 2022 — Presentation

Q4 2022PDF · 36 pages2.7 MB
Merck
Q4 2022 Earnings
February 2, 2023

-- 1 of 36 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 36 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will
receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

-- 3 of 36 --

Strategy &
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 36 --

Delivered on our key strategic priorities in 2022
5
Achieved strong commercial and
financial performance
Advanced the pipeline to meet patient
unmet need
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 36 --

Exceptional 2022 sales and underlying earnings growth1
6
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaborations and
licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. For 2020, non-GAAP results have been recast to
include $4.2 billion of incremental R&D expenses, which reduced EPS by $1.56. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D expense, which reduced EPS by
$0.65. For 2022, non-GAAP results include $690 million of R&D expense, or an estimated $0.22 of negative impact to EPS related to an asset acquisition, and collaboration and licensing agreements.
3. GAAP EPS of $1.18.
$41.5B
+6%
$48.7B
+17%
GUIDANCE
RANGE
$57.5B-$58.5B
$13.8B
+2%
4Q Worldwide Sales
$1.62
-10%
4Q Non-GAAP EPS2,3
2020 	2021 	2022
$41.5B
+6%
$48.7B
+17%
2020 	2021 	2022
$2.97
$5.37
Full Year Revenue
Full Year Non-GAAP EPS2
$59.3B
+22%
$7.48

-- 6 of 36 --

Advancing and augmenting pipeline
across multiple therapeutic areas in Q4
7
Oncology 	Cardiovascular
• 	Merck to present data for
sotatercept and MK-0616,
oral macrocyclic peptide
PCSK9 inhibitor, at
ACC.23/WCC
• 	Merck to host investor event
on March 6 th to discuss these
results
• 	Announced positive top line
results for the Phase 2 trial
evaluating KEYTRUDA in
combination with
mRNA-4157/V940, an
investigational personalized
mRNA therapeutic cancer
vaccine in adjuvant treatment
of patients with stage III/IV
melanoma following complete
resection
• 	Received FDA approval for
KEYTRUDA for the adjuvant
treatment of adult patients
with stage IB (T2a >=4 cm), II
or IIIA non-small cell lung
cancer following resection and
platinum-based chemotherapy
based on KN-091
Vaccines
• 	Merck collaborator
Instituto Butantan (IB)
announced positive topline
results from IB’s Phase 3
dengue vaccine candidate.
Results to inform next
steps for V181 program1
Business
Development
• 	Augmented pipeline with
new candidates from recent
business development
transactions, including:
o 	Collaborations with
Moderna and Kelun-
Biotech
o 	Acquisition of Imago
• 	In 2023, expect four Phase
3 trial starts from programs
added in 2022 through
business development
1. Both Merck and IB’s investigational vaccines are derived from materials licensed from the U.S. National Institutes of Health and both institutions are
evaluating formulations analogous to the NIH TV003 formulation.

-- 7 of 36 --

Enhance durable
growth drivers
Deploy cash flow to
value-enhancing BD
Leverage leadership
in oncology
Advance pipeline across
key therapeutic areas
Building a sustainable engine to drive success into the next decade
8
New combinations and
coformulations
New delivery mechanisms
New mechanisms of action
outside of
immuno-oncology
Cardiometabolic
Vaccines
Neuroscience
Infectious Disease/
Immunology
Additional immuno-
oncology approaches
Ample balance sheet
capacity
Disciplined approach
Pursuing the
best external science
Vaccines
Animal Health

-- 8 of 36 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 9 of 36 --

Merck achieved exceptional 2022 financial performance 1
10
WORLDWIDE SALES2
$59.3B+22% growth
+26% ex-exchange
+15% ex-exchange, LAGEVRIO4
NON-GAAP EPS33,5
$7.48+39% growth
+43% ex-exchange
Merck
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue; 3. Merck is providing certain 2022 and 2021 non-GAAP information that
excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in
part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
For a description of the non-GAAP adjustments, see Table 2a attached to the press release. Non-GAAP results for 2021 have been recast to conform to presentation changes implemented in
2022. 4. Excludes impact of foreign exchange and LAGEVRIO sales of $5.7B. 4. GAAP EPS of $5.71.

-- 10 of 36 --

Strong Q4 performance across Human Health and Animal Health
11
Merck
WORLDWIDE SALES1,2
$13.8B+ 2% growth
+8% ex-exchange
$12.2B
+1% growth
+9% ex-exchange
Human Health
$1.2B
-2% growth
+6% ex-exchange
Animal Health
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue

-- 11 of 36 --

Oncology: KEYTRUDA drives continued growth
12	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $5.5B increased 26%
year-over-year, driven by strong global
demand and expansion into new indications
– In the U.S., growth of 27% reflects strong
growth across all key tumor types, especially in
earlier-stage cancers such as high-risk, early-
stage TNBC
– Expect to launch earlier stage NSCLC indication
based on recent FDA approval of KEYNOTE-091
study
– Ex-U.S., 24% increase driven by continued
global uptake in metastatic indications, such as
NSCLC, H&N and RCC
• Strong uptake from recent launches in high-risk,
early-stage TNBC and RCC
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
4Q20 	4Q21 	4Q22
$4.6B
+16%
$4.0B
+27%
$5.5B
+26%

-- 12 of 36 --

Oncology: Robust performance across broad portfolio
• Lynparza 1 sales increased 14%, with growth
driven by continued demand in adjuvant
treatment of certain patients with
gBRCAm, HER2-negative high-risk early-
stage breast cancer
• Lenvima 2 sales grew 9% driven by increased
uptake in advanced RCC and advanced
endometrial cancer in the U.S.
• WELIREG continues to perform in line with
expectations providing a treatment option
for patients with certain VHL-associated
tumors
$248M
+34%	$178M
+62%
$275M
+17%
$181M
+15%
$151M
+57%
$231M
+33%
13	Growth rates exclude the impact of foreign exchange.
1 In collaboration with AstraZeneca; 2 In collaboration with Eisai
4Q20 	4Q21 	4Q22
4Q20 	4Q21 	4Q22
$268M
+33%	$206M
+53%
$292M
+14%
$206M
+31%	$158M
+26%
$216M
+9%

-- 13 of 36 --

Vaccines: Gardasil growth driven by strong global demand
14
• GARDASIL sales of $1.5B increased 6%
year-over-year primarily driven by strong
underlying demand outside the U.S.
– Ex-U.S., reflects demand driven growth,
particularly in China
– U.S. sales declined primarily due to CDC
purchasing patterns
• Pediatric launch of VAXNEUVANCE off to
an encouraging start; sales benefitted
from inventory stocking
$1.2B
+78%
$656M
-24%
$1.7B
+40%
4Q20 	4Q21 	4Q22
$1.5B
+50%
$998M
+41%
$1.5B
+6%
Growth rates exclude the impact of foreign exchange.

-- 14 of 36 --

Hospital: Strong global demand across key products
15
• BRIDION sales of $441M increased 7%
primarily due to greater share among
neuromuscular blockade reversal agents
and increase in surgical procedures
• PREVYMIS sales grew 28%, driven by
continued strong global demand
• ZERBAXA benefited from completion of
global resupply which started in Q4 2021
$387M
+67%
$224M
-18%
$426M
+15%
4Q20 	4Q21 	4Q22
$436M
+24%	$355M
+13%
$441M
+7%
$93M
+41%$63M
+67%
$103M
+18%
4Q20 	4Q21 	4Q22
$100M
+27%	$80M
+57%
$118M
+28%
Growth rates exclude the impact of foreign exchange.

-- 15 of 36 --

Animal Health: Solid growth driven by livestock
16
• Animal Health sales increased 6% to $1.2B,
reflecting strategic price actions and volume
growth
– Livestock sales grew 12% due to increased
demand in ruminants and poultry products
– Companion Animal sales decreased 5% due to
supply challenges for certain vaccines and a
reduction in vet visits in October, which
improved during the quarter
$1.5B
+27%
$1.1B
+3%
$1.5B
+5%
4Q20 	4Q21 	4Q22
$1.3B
+8%	$1.2B
+6%
$1.2B
+6%
Growth rates exclude the impact of foreign exchange.

-- 16 of 36 --

Q4 2022 continuing operations non-GAAP financial results summary1
Q4 2022 	Q4 2021 	Change Change
Ex-FX
Sales 	$13.8 	$13.5 	+2% 	+8%
Non-GAAP Gross
Margin 75.7% 	74.8% 	+0.9pts 	+0.3pts
Non-GAAP Operating
Expenses 2 $5.7 	$5.3 	+8% 	+12%
Non-GAAP Tax Rate 	15.6% 	4.3% 	+11.3pts 	N/A
Non-GAAP EPS 3 $1.62 	$1.81 	-10% 	-7%
$ in billions, except EPS amounts
17
1. Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the press release. Non-GAAP results for 2021 have been recast to conform to
presentation changes implemented in 2022. 2. Non-GAAP results include $690 million of R&D expense, or an estimated $0.22 of negative impact to EPS, related to an asset acquisition, and
collaboration and licensing agreements 3. Q4 2022 GAAP EPS of $1.18.

-- 17 of 36 --

Merck provides full-year 2023 guidance
1. GAAP Gross Margin Rate: ~73%. 2. GAAP Operating Expenses: $23.3 to $24.3 billion. 3. GAAP Tax Rate: ~17-18% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q4 2022 earnings
release 5. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in
transactions accounted for as asset acquisitions from its non-GAAP results.
Guidance 	Key Assumptions
Revenue $57.2B to $58.7B
-4% to -1% (-2% to +1% ex-FX)
• 	Includes approximately $1B of LAGEVRIO revenue
• 	Ex-LAGEVRIO, growth of 5% to 8% (7 to 10% ex-FX)
• 	Assumes ~2% FX headwind
Non-GAAP
Gross Margin Rate 1 	~77.0%
Non-GAAP
Operating Expenses 2 	$23.1B to $24.1B
• 	Includes $1.4B of upfront R&D expense related to acquisition of
Imago Biosciences and expansion of collaboration with Kelun
Biotech
Other (Income) / Expense 	~$250M of income • 	Assumes no pension settlement cost as well as an expectation of
higher interest income and higher joint venture equity income
Tax Rate3 	~17.0%-18.0% • 	Assumes unfavorable impact due to the R&D capitalization
provision, as well as ~1% unfavorable impact related to Imago
Shares Outstanding 	~2.55B
GAAP EPS 	$5.86 to $6.01
Non-GAAP EPS4,5 	$6.80 to $6.95
• 	Reflects upfront R&D expense $0.53 for Imago Biosciences and
Kelun Biotech
• 	Assumes ~4% FX headwind
18

-- 18 of 36 --

Key modeling considerations for 2023
19
Other Revenue
• 	Expect strong growth driven by
robust global demand, particularly in
ex-U.S. markets
• 	Increased ability to supply positions
us well to support significant
demand now and in the future
• 	Expect significant decline, resulting
from smaller planned benefit from
revenue hedges following U.S. dollar
strength in 2022
o Resulted in an ~$800M benefit in 2022
• 	Reflects discontinuation of third-
party manufacturing sales to
Johnson and Johnson
GARDASIL 	Other (Income) / Expense
and Tax Rate
• 	Other Income assumes no pension
settlement cost; expect higher
interest income and joint venture
equity income
• 	Tax Rate assumes unfavorable
impact of R&D capitalization
provision and approximate 1 ppt
unfavorable impact related to the
Imago transaction

-- 19 of 36 --

20
Continue to prioritize
investments in our
pipeline and business
to realize value
of near- and long-term
opportunities
$2.6
$1.1
$1.7
$0.3 	$0.0
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions 1
1. Reflects Q4 spend
Remain committed to balanced capital allocation strategy
Capital allocation order of priority

-- 20 of 36 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 21 of 36 --

22
Working to help transform the landscape of cancer
treatment by focusing on earlier stages of disease
Advancing our collaboration with Moderna to leverage
mRNA technology with KEYTRUDA to target the
unique mutational signature of each patient’s tumor in
melanoma and other tumor types
KEYTRUDA
Immunotherapy that
increases the ability of
the body’s immune
system to help detect
and fight tumor cells
mRNA-4157/V940
Designed to stimulate
an immune response
by generating specific
T cell responses based on
the unique mutational
signature of a
patient’s tumor
Making progress in the treatment of earlier stage
non-small cell lung cancer through various clinical trials
APPROVED
PHASE III
• 	KEYNOTE-091: Received FDA approval for KEYTRUDA for
adjuvant treatment of adult patients with stage IB (T2a >=4
cm), II or IIIA NSCLC following resection and platinum-based
chemotherapy
• 	KEYNOTE-671: Evaluating KEYTRUDA with platinum doublet
chemotherapy as neoadjuvant followed by adjuvant therapy for
patients with resectable stage II, IIIA and IIIB NSCLC
• 	KEYNOTE-867: Evaluating KEYTRUDA in patients undergoing
stereotactic body radiotherapy with unresected stage I or II
NSCLC
• 	KEYLYNK-012: Evaluating KEYTRUDA in combination with
Lynparza1 in stage III disease
1 In collaboration with AstraZeneca

-- 22 of 36 --

23
Advancing our broader oncology portfolio
Hematology 	Tissue Targeting
Therapies
Ex-U.S. Approvals	Positive Data Readouts
• In Europe:
– Received approval for
Lynparza1 in combination
with abiraterone and
prednisone or prednisolone
for the treatment of certain
patients with mCRPC based
on PROpel
• In China:
– Received approval for
KEYTRUDA in neoadjuvant /
adjuvant high-risk, early-
stage TNBC based on KN-522
– Received approval for
KEYTRUDA in hepatocellular
carcinoma based on KN-394
• Announced acquisition of
Imago Biosciences:
– Lead candidate
bomedemstat a potentially
first-in-class orally available
lysine-specific demethylase 1
inhibitor (LSD-1)
• Presented data at American
Society of Hematology
Meeting for:
– favezelimab (anti-LAG3)
– zilovertamab vedotin (ROR-1)
– nemtabrutinib (BTKi)
– KEYTRUDA
• Padcev2: FDA accepted sBLA
for Keytruda to be used in
combination with Padcev, an
ADC targeting Nectin-4, for 1L
treatment of certain patients
with locally advanced or
metastatic urothelial cancer
who are ineligible for cisplatin-
containing chemotherapy
• Kelun-Biotech: Expanded
collaboration with up to 7
additional preclinical antibody
drug conjugate candidates
• PeptiDream: Expanded
ongoing collaboration for the
discovery and development of
peptide drug conjugates
• KEYNOTE-966: Announced
positive Phase III results
evaluating KEYTRUDA in
combination with
chemotherapy in 1L treatment
of advanced or unresectable
biliary tract cancer
• KEYNOTE-859: Announced
positive Phase III results
evaluating KEYTRUDA in
combination with
chemotherapy in HER2-
negative locally advanced
unresectable or metastatic
gastric or gastroesophageal
junction adenocarcinoma
1. In collaboration with Astra Zeneca 2. In collaboration with Astellas and Seagen. Padcev is a registered trademark of Seagen and Agensys.

-- 23 of 36 --

24
Focusing on important unmet medical needs through
vaccine development programs
• 	Receiving positive feedback from physicians following
launch of VAXNEUVANCE in the pediatric setting
• 	VAXNEUVANCE offers strong immunogenicity, including
in the first year of life where incidence of IPD is greatest
within the healthy pediatric population
Pneumococcal Disease Chart
Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Core surveillance (ABCs).
Active Bacterial Core Surveillance (ABCs) report emerging infections program network streptococcus pneumoniae, 2019. Available: SPN Surveillance Report 2019.pdf (cdc.gov).
Source: Epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US children, Ryan Gierke, MPH.
Advisory Committee on Immunization Practices, February 24 th , 2022.
• 	Collaborating with Instituto Butantan (IB) to conduct a
detailed analysis of IB’s positive Phase 3 data in order to
determine further clinical development of Merck’s
vaccine candidate, V181
V181 is being investigated
to help provide, in a single
dose, protection against all
four dengue serotypes
regardless of prior
exposure to dengue
Dengue 	Invasive Pneumococcal Disease

-- 24 of 36 --

25
Recent data published on cancer incidence
Among women ages 20
to 24, cervical cancer
incidence rates declined
by a total of … 65% from
2012 through 2019. 1
• 	We, along with others in the industry, are making a
real impact in our goal to help reduce cancer incidence
• 	American Cancer Society published its annual report
on cancer facts and trends
• 	Reinforces our commitment to bringing forward
treatment and prevention options to help patients
- American Cancer Society
Cervical Cancer
1. Cancer statistics, 2023, Rebecca L. Siegel, CA Cancer J Clin. 2023; 73:17–48

-- 25 of 36 --

26
Significant advancements across our broader pipeline and portfolio
• 	Granted conditional marketing authorization for
LAGEVRIO by China's National Medical Products
Administration
• 	Under Emergency Use Authorization, LAGEVRIO
remains an important treatment option as the COVID-
19 pandemic continues to evolve
COVID-19 	Cardiovascular
At ACC.23/WCC on March 6th, Merck to:
• 	Present results from Phase 3 STELLAR study evaluating
sotatercept for treatment of pulmonary arterial
hypertension
• 	Present data from Phase 2 study evaluating MK-0616,
oral macrocyclic peptide PCSK9 inhibitor, for treatment
of hypercholesterolemia
• 	Host live investor event

-- 26 of 36 --

Strong progress across our pipeline throughout 2022
27	1. Both Merck and IB’s investigational vaccines are derived from materials licensed from the U.S. National Institutes of Health and both institutions are evaluating formulations analogous
to the NIH TV003 formulation. 2. nucleoside reverse transcriptase translocation inhibitor
• VAXNEUVANCE: Received
approval in the pediatric setting
• V116: Received Breakthrough
Therapy Designation and
advanced into Phase 3 trials for
the prevention of invasive
pneumococcal disease and
pneumococcal pneumonia in
adults
• V181: Merck collaborator Instituto
Butantan (IB) announced positive
topline results from IB’s Phase 3
dengue vaccine candidate.
Results to inform next steps for
V181 program1
Cardiometabolic 	Infectious Disease	Vaccines
• Sotatercept: Announced positive
topline results for Phase 3
STELLAR trial in PAH
• MK-0616: Completed Phase 2
trial in patients with
hypercholesterolemia
• MK-2060: Received Fast Track
designation for the reduction in
risk of major thrombotic
cardiovascular events in patients
with ESRD
• MK-5475: Initiated Phase 2 study
in patients with
PH-COPD
• Islatravir: Reinitiated
development program in the HIV
treatment setting
• MK-8527: Initiated Phase 1b
study of internal novel NRTTI 2 for
HIV PrEP
• LAGEVRIO: Initiated Phase 2 trial
for the treatment of RSV
Oncology
• KEYTRUDA:
– Received approval for advanced
endometrial cancer that is MSI-H
or dMMR (KN-158)
– Received approval for KN-091 for
adjuvant treatment of adult
patients with stage IB (T2a >=
4cm), II or IIIA NSCLC following
resection and platinum-based
chemotherapy
– Announced positive topline results
for HER2- locally advanced
unresectable or metastatic gastric
or GEJ adenocarcinoma (KN-859)
• Lynparza: Received approval for
adjuvant treatment of adults with
gBRCAm, HER2- high-risk early
breast cancer (OlympiA)
• MRNA-4157/V940: Announced
positive topline results for Phase 2b
trial in adjuvant treatment in
patients with stage III/IV melanoma
following complete resection

-- 27 of 36 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 28 of 36 --

Appendix
29

-- 29 of 36 --

$404
$580 $704
$876
2019 	2020 	2021 	2022
$444
$725
$989 $1,116
2019 	2020 	2021 	2022
$11,084
$14,380
$17,186
$20,937
2019 	2020 	2021 	2022
Sustained strong full-year performance across key growth pillars
All growth rates exclude the impact of foreign exchange.
$ In millions.
Lynparza in collaboration with AstraZeneca. Lenvima in collaboration with Eisai.
$1,131 	$1,198
$1,532 $1,685
2019 	2020 	2021 	2022
$3,737 	$3,938
$5,673
$6,897
2019 	2020 	2021 	2022
$4,393 $4,703
$5,568 	$5,550
2019 	2020 	2021 	2022
+6%
YOY
+27%
YOY
+16%
YOY
+28%
YOY
+18%
YOY
+27%
YOY
30

-- 30 of 36 --

Q4 2022 continuing operations GAAP financial results summary
31
Q4 2022 	Q4 2021 	Change Change
Ex-FX
Sales 	$13.8 	$13.5 	+2% 	+8%
Operating Expenses 	$6.5 	$5.9 	+10% 	+13%
Tax Rate 	14.1% 	2.2% 	+11.9pts 	N/A
GAAP EPS 	$1.18 	$1.51 	-22% 	-17%
$ in billions, except EPS amounts

-- 31 of 36 --

2022 continuing operations GAAP financial results summary:
32
2022 	2021 	Change Change
Ex-FX
Sales 	$59.3 	$48.7 	+22% 	+26%
Operating Expenses 	$23.6 	$21.9 	+8% 	+11%
Tax Rate 	11.7% 	11.0% 	+0.7pts 	N/A
GAAP EPS 	$5.71 	$4.86 	+17% 	+21%
$ in billions, except EPS amounts

-- 32 of 36 --

2022 continuing operations non-GAAP financial results summary:
Delivered strong revenue and EPS growth
2022 	2021 	Change Change
Ex-FX
Sales 	$59.3 	$48.7 	+22% 	+26%
Non-GAAP Gross
Margin1 74.4% 	76.1% 	-1.7pts 	-2.1pts
Operating Expenses 	$21.6 	$21.0 	+3% 	+6%
Tax Rate 	14.2% 	12.4% 	+1.8pts 	N/A
Non-GAAP EPS that
excludes certain items 1 $7.48 	$5.37 	+39% 	+43%
$ in billions, except EPS amounts
33
1. Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying
business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how
management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other
metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute
for or superior to, information prepared in accordance with GAAP.

-- 33 of 36 --

$10.2
$4.4
$7.0
$2.4 	$0.0
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$ 18B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$2.92
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
$3.20
2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023
Dollars per share	
+2% 	+2% 	+2% +2% 	+2%
+11%
+15%
+7%
Over the past 12 months
Capital investments
2022 to 2026
Commitment to the dividend
34
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%
Order of priority
+6%
E
1. Includes payments reflected in operating cash flow
1

-- 34 of 36 --

Driving value for patients and shareholders by progressing our pipeline
35
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the U.S.:
o The FDA granted approval of KEYTRUDA following
surgical resection and platinum-based chemotherapy
in patients with stage IB, II or IIIA non-small cell lung
cancer based on KN-091, as well as accepted
submission of Supplemental Biologics License
Applications for PADCEV1 + KEYTRUDA to be used in
combination as 1L treatment of certain patients with
locally advanced or metastatic urothelial cancer who
are ineligible for cisplatin-containing chemotherapy
based on KN-869
• 	In Europe:
o Received approval for Lynparza2 in combination with
abiraterone and prednisone or prednisolone in
certain patients with metastatic castration-resistant
prostate cancer based on PROpel
• 	In China:
o Received approval for KEYTRUDA in patients with
high-risk early-stage TNBC in combination with
chemotherapy as neoadjuvant treatment based on
KN-522, as well as conditional marketing
authorization for LAGEVRIO in adult patients with
mild to medium COVID-19 infection and a high risk of
progressing to severe cases
• 	In Japan:
o Completed submission of KN-170/KN-A33 in
patients with relapsed or refractory primary
mediastinal large B-cell lymphoma
1. In collaboration with Astellas and Seagen. Padcev is a registered trademark of Seagen and Agensys. 2. In collaboration with AstraZeneca.
• 	Announced with partner Moderna, positive topline
results from Phase 2b KN-942 trial evaluating mRNA-
4157/V940, an investigational personalized mRNA
cancer vaccine in combination With KEYTRUDA
• 	Announced positive topline results from Phase 3 KN-
859 trial evaluating KEYTRUDA in combination with
chemotherapy for 1L treatment in patients with HER2-
negative locally advanced unresectable or metastatic
gastric or gastroesophageal junction (GEJ)
adenocarcinoma
• 	Presented data across broad hematology pipeline and
portfolio at ASH, including for favezelimab (MK-4280),
zilovertamab vedotin (MK-2140), nemtabrutinib (MK-
1026) and KEYTRUDA
• 	Announced publication of updated systematic
literature review examining the global impact and
effectiveness of GARDASIL across 138 studies
• 	Initiated Phase 3 studies for MK-1026 in hematologic
malignancies

-- 35 of 36 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V181
Dengue Fever Virus
Vaccines
Infectious diseases
MK-8189 4
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US, EU)
General medicine
General medicine
As of February 17, 2023
V114
Pneumococcal Vaccine, pediatric (JPN)
Vaccines
Infectious diseases
Oncology 	Oncology
MK-1942
Treatment Resistant Depression
MK-6024 (efinopegdutide)
NASH
MK-7075 (miransertib)
Overgrowth Syndrome
MK-8591B (islatravir+MK-8507)1
HIV-1 Infection
MK-8591D (islatravir+lenacapavir)2
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary Tract
CSCC (EU)
Gastric (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
Prostate
SCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-7684A (vibostolimab
+pembrolizumab)
Melanoma
NSCLC
SCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological Malignancies
LENVIMA (MK-7902)
CRC
Esophageal
Gastric
HNSCC
Melanoma
NSCLC
LYNPARZA (MK-7339)
NSCLC
SCLC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
CRC
MK-3475
(pembrolizumab
subcutaneous)
NSCLC
MK-3475A
(pembrolizumab
+hyaluronidase)
NSCLC
MK-8591A (doravirine+islatravir)2
HIV-1 Infection
LAGEVRIO (MK-4482)3
COVID-19 antiviral
KEYTRUDA (MK-3475)
1L Urothelial (US)
2L HCC (US)
LA Merkel Cell (US)
Adjuvant NSCLC (EU)
B-Cell Lymphoma (JPN)
LYNPARZA (MK-7339)
Metastatic 1L Prostate (US, JPN)
MK-0616
Hypercholesterolemia
MK-2060
Thrombosis
MK-5475
Pulmonary Arterial Hypertension
MK-7962 (sotatercept)
Pulmonary Hypertension due to Left
Heart Disease
Cardiovascular
MK-4830
CRC
Esophageal
Melanoma
NSCLC
Ovarian
RCC
SCLC
MK-5684
Prostate
MK-5890 (boserolimab)
NSCLC
SCLC
MK-6440
(ladiratuzumab vedotin)
Breast
Esophageal
Gastric
HNSCC
Melanoma
NSCLC
Prostate
SCLC
MK-2870
Neoplasm Malignant
KEYTRUDA (MK-3475)
Advanced Solid Tumors
MK-3543
(bomedemstat)
Myeloproliferative
Disorders
MK-4280
(favezelimab)
NSCLC
MK-4280A
(favezelimab+pembroli
zumab)
Esophageal
Melanoma
RCC
SCLC
WELIREG (MK-6482)
Biliary
Certain VHL tumors (EU)
CRC
Endometrial
Esophageal
HCC
Pancreatic
Rare Cancers
LYNPARZA (MK-7339)
Advanced Solid Tumors
LENVIMA (MK-7902)
Biliary
Pancreas
Prostate
SCLC
mRNA-4157/V940
Melanoma
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Hematological Malignancies
Ovarian
Prostate
TUKYSA (MK-7119)
Advanced Solid Tumors
Bladder
Biliary
Cervical
Endometrial
Gastric
NSCLC
MK-0482
NSCLC
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
HCC
Melanoma
SCLC
MK-2140 (zilovertamab
vedotin)
Bladder
Breast
Gastric
Hematological Malignancies
NSCLC
Ovarian
Pancreas
Broad and innovative pipeline to solve significant unmet medical needs
36
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial
Virus (RSV)
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma
MK-7962 (sotatercept)
Pulmonary Arterial Hypertension
Cardiovascular
Infectious diseases
LAGEVRIO (MK-4482)
COVID-19 antiviral (EU)
V116
Pneumococcal vaccine,
adult
Hospital
PREVYMIS (MK-8228)
Prophylaxis of CMW in kidney transplant patients

-- 36 of 36 --